Ejso最新文献

{"title":"Surgery-related change in cancer cell adhesion associates with recurrence in patients undergoing colorectal cancer surgery","authors":"Stine Bull Jessen ,&nbsp;Rasmus Peuliche Vogelsang ,&nbsp;Troels Gammeltoft Dolin ,&nbsp;Jannie Jørgensen ,&nbsp;Josephine Bjergbæk Olsson ,&nbsp;Tove Kirkegaard ,&nbsp;Ismail Gögenur ,&nbsp;Jesper Thorvald Troelsen","doi":"10.1016/j.ejso.2025.110055","DOIUrl":"10.1016/j.ejso.2025.110055","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to investigate the effect of pre- and postoperative serum on the adhesion of cultured colon cancer cells and their relationship with colorectal cancer recurrence.</div></div><div><h3>Background</h3><div>Colorectal cancer is common, and surgery is the primary treatment choice. However, surgical procedures may be associated with an increased risk of recurrence.</div></div><div><h3>Method</h3><div>434 patients undergoing curatively intended colorectal cancer surgery at Copenhagen University Hospital, Herlev, Denmark, between July 15, 2014, and March 31, 2019, were included in the study. Pre- and postoperative serum samples were collected, and the effect on cellular adhesion was analyzed using a novel high-throughput approach based on CRISPR/Cas9 modified Caco-2 cells and secreted luciferase, named the AdhesionScore assay. The relative risk of postoperative recurrence was estimated using Cox proportional regression analysis.</div></div><div><h3>Results</h3><div>The difference in adhesion between modified Caco-2 cells seeded in the pre- and postoperative serum showed a significant increase in postoperative adhesion in patients with a recurrence event (p=0.0293). Modeling the adhesion data using multiple logistic regression and Cox proportional regression analyses showed a statistically significant association between increased postoperative adhesion and recurrence (p=0.0155 and p=0.0126, respectively). Patients with the highest AdhesionScore showed the greatest risk of recurrence (HR=7, 95% CI 1.6-37.8, p=0.0130).</div></div><div><h3>Conclusions</h3><div>The study found that a difference in the adhesion of Caco-2 cells seeded in pre- and postoperative serum was associated with cancer recurrence following intended curative surgery. This suggests that increased postoperative adhesion may serve as a novel biological marker of recurrence in patients undergoing surgery for colorectal cancer.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110055"},"PeriodicalIF":3.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Optimized machine learning model for predicting unplanned reoperation after rectal cancer anterior resection\"","authors":"Souichi Oka,&nbsp;Yoshiyasu Takefuji","doi":"10.1016/j.ejso.2025.110025","DOIUrl":"10.1016/j.ejso.2025.110025","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110025"},"PeriodicalIF":3.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Segmentectomy versus lobectomy for intersegmental small-sized non-small cell lung cancer","authors":"Shengzhe Zhou ,&nbsp;Shusheng Zhu ,&nbsp;Zhihua Li ,&nbsp;Zhicheng He ,&nbsp;Wenzheng Xu ,&nbsp;Xianglong Pan ,&nbsp;Weibing Wu ,&nbsp;Liang Chen","doi":"10.1016/j.ejso.2025.110051","DOIUrl":"10.1016/j.ejso.2025.110051","url":null,"abstract":"<div><h3>Objectives</h3><div>Intersegmental non-small cell lung cancer (NSCLC) represents a type of lesion involving at least two segments. This study aimed to demonstrate the characteristics of intersegmental NSCLC and compare the prognosis of segmentectomy with lobectomy for intersegmental NSCLC.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted on patients with small-sized NSCLC who underwent segmentectomy or lobectomy between January 2012 and December 2020. Intersegmental and non-intersegmental nodules were determined by three-dimensional computed tomographic bronchography and angiography. The log-rank test and Cox hazard proportional regression were adopted for prognostic analyses.</div></div><div><h3>Results</h3><div>Totally, 1702 patients with 425 intersegmental nodules (25 %) and 1277 non-intersegmental nodules (75 %) were enrolled. Among eligible patients, 1086 patients accepted segmentectomy (intersegmental n = 188, non-intersegmental n = 898) and 616 patients underwent lobectomy (intersegmental n = 237, non-intersegmental n = 379). Intersegmental nodules were associated with larger tumor size and more lymph node metastasis (5.4 % vs. 2.1 %, P = 0.001), while intersegmental NSCLC achieved a similar prognosis to non-intersegmental NSCLC. Segmentectomy for intersegmental nodules required longer operative times, resection of more subsegments (4.06 vs. 2.91, <em>P</em> &lt; 0.001), and larger resected lung volumes compared to that for non-intersegmental nodules. For patients with intersegmental nodules, the lobectomy group had larger tumor sizes, more solid nodules, and more lymph node metastasis than the segmentectomy group. After propensity score-matching, segmentectomy (n = 75) yielded comparable 5-year overall survival and disease-free survival with the lobectomy (n = 75).</div></div><div><h3>Conclusion</h3><div>Intersegmental nodules demonstrate a prognosis similar to non-intersegmental nodules, despite showing a higher rate of lymph node metastasis. Segmentectomy achieved long-term outcomes comparable to lobectomy for selected intersegmental NSCLC.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110051"},"PeriodicalIF":3.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply letter to: Specialised oncology training for effective multidisciplinary cancer care","authors":"I.T. Rubio ,&nbsp;Lynda Wyld","doi":"10.1016/j.ejso.2025.110033","DOIUrl":"10.1016/j.ejso.2025.110033","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110033"},"PeriodicalIF":3.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Development and validation of a comprehensive predictive model for surgical planning in patients with renal cell carcinoma and inferior vena cava tumor thrombus”","authors":"Mengyuan Zhang ,&nbsp;Kangyu Wang","doi":"10.1016/j.ejso.2025.110031","DOIUrl":"10.1016/j.ejso.2025.110031","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110031"},"PeriodicalIF":3.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of view","authors":"Woong Ki Park ,&nbsp;Seok Jin Nam ,&nbsp;Seok Won Kim ,&nbsp;Jonghan Yu ,&nbsp;Se Kyung Lee ,&nbsp;Jai Min Ryu ,&nbsp;Byung Joo Chae ,&nbsp;Dong Seung Shin ,&nbsp;Jin Seok Ahn ,&nbsp;Yeon Hee Park ,&nbsp;Ji-Yeon Kim ,&nbsp;Junghoon Shin ,&nbsp;Hee Kyung Ahn ,&nbsp;Eun Yoon Cho ,&nbsp;Hyunwoo Lee ,&nbsp;Jeong Eon Lee","doi":"10.1016/j.ejso.2025.110011","DOIUrl":"10.1016/j.ejso.2025.110011","url":null,"abstract":"<div><h3>Purpose</h3><div>Neoadjuvant pembrolizumab has shown efficacy in improving pathologic complete response (pCR) rates and survival outcomes in triple-negative breast cancer (TNBC). However, real-world data on its clinical efficacy, safety, and surgical outcomes remain limited.</div></div><div><h3>Materials and methods</h3><div>This retrospective observational study included 331 TNBC patients treated at a single institution from July 2022 to December 2023. Patients received weekly paclitaxel with carboplatin followed by doxorubicin and cyclophosphamide (AC), with or without pembrolizumab. Primary outcomes included pCR rates and surgical de-escalation in the breast and axilla. Secondary outcomes included event-free survival (EFS), overall survival (OS), surgical complications, and persistent immune-related adverse events (irAEs).</div></div><div><h3>Results</h3><div>The pCR rate was higher in the pembrolizumab group (57.7 %) compared to the control group (49.1 %), with an estimated difference of 8.5 % (p = 0.120). Pembrolizumab enabled 32.7 % of patients initially planned for mastectomy to undergo breast-conserving surgery (BCS). Axillary lymph node dissection (ALND) was avoided in 91 % of pembrolizumab-treated patients versus 86.9 % in the control group. Persistent irAEs were observed in 10.9 % of the pembrolizumab group, with thyroid dysfunction being the most common. Surgical complications were similar between groups. Short-term oncologic outcomes, including EFS and OS, did not differ significantly after a median follow-up of 21 months.</div></div><div><h3>Conclusion</h3><div>Pembrolizumab demonstrated potential benefits in increasing pCR rates and facilitating surgical de-escalation while maintaining comparable safety to conventional regimens. Persistent irAEs underscore the need for preoperative management and vigilant monitoring. Future studies should identify predictive biomarkers to optimize pembrolizumab's use and assess its long-term impact on survival outcomes.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110011"},"PeriodicalIF":3.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Is liver resection still required for patients who have predictive factors for complete pathologic necrosis after downstaging treatments of locally advanced hepatocellular carcinoma?”","authors":"Liheng Liu ,&nbsp;Xu Wang ,&nbsp;Jinkai Feng ,&nbsp;Shuqun Cheng","doi":"10.1016/j.ejso.2025.110032","DOIUrl":"10.1016/j.ejso.2025.110032","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110032"},"PeriodicalIF":3.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specialised oncology training for effective multidisciplinary cancer care","authors":"Pallvi Kaul,&nbsp;Pankaj Kumar Garg","doi":"10.1016/j.ejso.2025.110027","DOIUrl":"10.1016/j.ejso.2025.110027","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110027"},"PeriodicalIF":3.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advantages of robotic-assisted thoracic surgery after neoadjuvant therapy in NSCLC: A propensity score–matched analysis","authors":"Hong-Ji Li ,&nbsp;Jia-Yan Ding ,&nbsp;Qiang Nie ,&nbsp;Hui-Zhao Hong ,&nbsp;Zhen-Bin Qiu ,&nbsp;Rui Fu ,&nbsp;Chao Zhang ,&nbsp;Jia-Tao Zhang ,&nbsp;Zi-Yi Xu ,&nbsp;Jie Yang ,&nbsp;Sheng Zhang ,&nbsp;Jun-Tao Lin ,&nbsp;Xue-Ning Yang ,&nbsp;Ben-Yuan Jiang ,&nbsp;Wen-Zhao Zhong","doi":"10.1016/j.ejso.2025.110022","DOIUrl":"10.1016/j.ejso.2025.110022","url":null,"abstract":"<div><h3>Background</h3><div>Robot-assisted thoracic surgery (RATS) was advantageous in complex procedures. Neoadjuvant therapy leads to intra-operative difficulty in non-small cell lung cancer (NSCLC). The aim of this study was to compare RATS and video-assisted thoracic surgery (VATS) in neoadjuvant setting.</div></div><div><h3>Methods</h3><div>This retrospective study included stage II-IIIB(N2) NSCLC patients who underwent surgery after receiving neoadjuvant therapy. Patients were grouped by RATS or VATS. The primary outcomes are R0 resection rate, operation time and estimated blood loss. The secondary outcome is the rate of conversion to thoracotomy. Demographic data, clinical data and pathological data were collected for analysis. Propensity score matching (PSM) was applied to balance bias.</div></div><div><h3>Results</h3><div>Between July 2021 and June 2024, 118 patients received RATS and 317 patients received VATS were included. Before PSM, RATS was associated with a significantly shorter operative time (194 min vs. 223 min, p &lt; 0.001) and a lower conversion rate to thoracotomy (8.47 % vs. 18.6 %, p = 0.015). However, no significant differences were observed in the R0 resection rate (p = 0.306) or mean estimated blood loss (p = 0.371). After PSM, RATS still demonstrated advantages in operation time (194 min vs 223 min, p = 0.001), reducing conversion caused by fibrosis or difficult exposure (p = 0.005), and number of N2 lymph nodes (p = 0.02). Single and multiple regressions both suggested RATS was associated with shorter operation time and lower conversion rate.</div></div><div><h3>Conclusions</h3><div>Our study suggested that RATS is a superior approach compared with VATS in neoadjuvant context, with advantages in shortening operation time, reducing conversion rate, and lymph node dissection.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110022"},"PeriodicalIF":3.5,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization and clinical outcomes of rare biliary adenosquamous carcinoma","authors":"Anne Ruffat ,&nbsp;Franck Monnien ,&nbsp;Chloé Molimard ,&nbsp;Julie Henriques ,&nbsp;Francine Fein ,&nbsp;Alexandre Doussot ,&nbsp;Lucine Vuitton ,&nbsp;Christophe Borg ,&nbsp;Angélique Vienot","doi":"10.1016/j.ejso.2025.110015","DOIUrl":"10.1016/j.ejso.2025.110015","url":null,"abstract":"<div><h3>Background</h3><div>Data are scarce regarding biliary adenosquamous carcinoma (BASC) due to its low incidence. BASC displays a worse prognosis than adenocarcinoma and its specific treatment is still an unmet medical need. We conducted a description analysis of BASC including clinicopathologic parameters and treatment outcomes.</div></div><div><h3>Methods</h3><div>All consecutive patients with histologically proven BASC diagnosed in six French hospitals between 2000 and 2022 were enrolled and described.</div></div><div><h3>Results</h3><div>A total of 16 BASC, accounting for 1.4 % of all biliary tract carcinoma, were included and the BASC incidence increased steadily over the past 22 years. The median age at diagnosis was 70.7 years (min-max 31.4–82.0 years) with most women (62.5 %). At diagnosis, half of BASC patients had a localized stage. The primary tumor locations were shared between gallbladder cancers (n = 7) and cholangiocarcinoma (n = 7), with mainly an extra-hepatic disease (71.4 %). Median overall survival was 9.5 months (95 % CI = 2.1–14.8 months). A total of 13 (81.6 %) patients had undergone surgery with a median relapse-free survival of 3.8 months (95 % CI = 0.0–10.5 months). Five (38.5 %) patients received an adjuvant chemotherapy. A total of seven (43.8 %) patients were treated with chemotherapy for the occurrence of metastases with a median progression-free survival of 2.8 months (95 % CI = 0.8–4.1 months). No objective response was observed and stable disease was achieved in two patients (28.6 %).</div></div><div><h3>Conclusions</h3><div>BASC is a rare disease with an increased incidence, highlighting the diagnostic challenges. BASC population was associated with a poor prognostic and limited therapeutic response. Further molecular investigations should be performed to investigate new therapeutic options.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 8","pages":"Article 110015"},"PeriodicalIF":3.5,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}